Resources by service
Embracing LEAN strategy to deliver patient-critical expanded access
Expanded access or compassionate use of investigational drugs provides a lifeline to certain patients, improving their quality of life or extending life expectancy. Yet it can also present clinical supply chain challenges and increase pressure on manufacturing operations to deliver vital therapeutic drugs, outside of normal procedures.
This was the case for one small, clinical stage biopharmaceutical company committed to developing treatments for a group of rare and ultimately fatal diseases. During phase I of a blinded trial, a patient was identified as a compassionate use case and Almac was committed to expediting drugs that were needed to halt the progression of the patient’s disease.
Download our latest Case Study to find out how Almac Clinical Services used a LEAN approach to drastically shorten the standard timelines associated with packaging and labelling drugs for the compassionate use patient.
If you require any further information, please contact Almac Clinical Services.
*By submitting your information you acknowledge that you have read the privacy statement and you consent to our processing the data in accordance with that privacy statement. We may, from time to time, send you material relevant to your interests. If you change your mind at any time about wishing to receive material from us, you can send an email to [email protected]. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list.